Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 2
1998 2
1999 2
2000 2
2001 2
2002 2
2003 6
2006 1
2008 2
2010 1
2011 2
2016 2
2020 2
2021 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P; ETHOS Investigators. Rabe KF, et al. N Engl J Med. 2020 Jul 2;383(1):35-48. doi: 10.1056/NEJMoa1916046. Epub 2020 Jun 24. N Engl J Med. 2020. PMID: 32579807 Clinical Trial.
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators. Harrison TW, et al. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. Lancet Respir Med. 2021. PMID: 33357499 Clinical Trial.
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy.
Louis R, Harrison TW, Chanez P, Menzella F, Philteos G, Cosio BG, Lugogo NL, de Luiz G, Burden A, Adlington T, Keeling N, Kwiatek J, Garcia Gil E; ANDHI Study Investigators. Louis R, et al. J Allergy Clin Immunol Pract. 2023 Jun;11(6):1759-1770.e7. doi: 10.1016/j.jaip.2023.03.009. Epub 2023 Mar 21. J Allergy Clin Immunol Pract. 2023. PMID: 36948488 Free article.
Asymptomatic infection with Borrelia burgdorferi.
Steere AC, Sikand VK, Schoen RT, Nowakowski J. Steere AC, et al. Among authors: sikand vk. Clin Infect Dis. 2003 Aug 15;37(4):528-32. doi: 10.1086/376914. Epub 2003 Jul 30. Clin Infect Dis. 2003. PMID: 12905137 Clinical Trial.
Persistent parasitemia after acute babesiosis.
Krause PJ, Spielman A, Telford SR 3rd, Sikand VK, McKay K, Christianson D, Pollack RJ, Brassard P, Magera J, Ryan R, Persing DH. Krause PJ, et al. Among authors: sikand vk. N Engl J Med. 1998 Jul 16;339(3):160-5. doi: 10.1056/NEJM199807163390304. N Engl J Med. 1998. PMID: 9664092 Free article.
Atovaquone and azithromycin for the treatment of babesiosis.
Krause PJ, Lepore T, Sikand VK, Gadbaw J Jr, Burke G, Telford SR 3rd, Brassard P, Pearl D, Azlanzadeh J, Christianson D, McGrath D, Spielman A. Krause PJ, et al. Among authors: sikand vk. N Engl J Med. 2000 Nov 16;343(20):1454-8. doi: 10.1056/NEJM200011163432004. N Engl J Med. 2000. PMID: 11078770 Free article. Clinical Trial.
Prospective study of serologic tests for lyme disease.
Steere AC, McHugh G, Damle N, Sikand VK. Steere AC, et al. Among authors: sikand vk. Clin Infect Dis. 2008 Jul 15;47(2):188-95. doi: 10.1086/589242. Clin Infect Dis. 2008. PMID: 18532885 Free PMC article.
Increasing health burden of human babesiosis in endemic sites.
Krause PJ, McKay K, Gadbaw J, Christianson D, Closter L, Lepore T, Telford SR 3rd, Sikand V, Ryan R, Persing D, Radolf JD, Spielman A; Tick-Borne Infection Study Group. Krause PJ, et al. Among authors: sikand v. Am J Trop Med Hyg. 2003 Apr;68(4):431-6. Am J Trop Med Hyg. 2003. PMID: 12875292
32 results